These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 38543764)
1. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review. Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764 [TBL] [Abstract][Full Text] [Related]
2. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review. Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338 [No Abstract] [Full Text] [Related]
3. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299 [TBL] [Abstract][Full Text] [Related]
4. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Greig SL; Deeks ED Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454 [TBL] [Abstract][Full Text] [Related]
5. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings. Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504 [TBL] [Abstract][Full Text] [Related]
6. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings. Ndashimye E; Arts EJ Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682 [TBL] [Abstract][Full Text] [Related]
7. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection. Santevecchi BA; Miller S; Childs-Kean LM Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review. Blanco-Arévalo JL; García-Deltoro M; Torralba M; Vélez-Díaz-Pallarés M; Castro A; Rubio-Rodríguez D; Rubio-Terrés C AIDS Rev; 2024; 26(2):67-79. PubMed ID: 39134019 [TBL] [Abstract][Full Text] [Related]
10. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study. Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677 [TBL] [Abstract][Full Text] [Related]
11. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Hocqueloux L; Raffi F; Prazuck T; Bernard L; Sunder S; Esnault JL; Rey D; Le Moal G; Roncato-Saberan M; André M; Billaud E; Valéry A; Avettand-Fènoël V; Parienti JJ; Allavena C; Clin Infect Dis; 2019 Oct; 69(9):1498-1505. PubMed ID: 30601976 [TBL] [Abstract][Full Text] [Related]
12. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort. Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST). Egger M; Sauermann M; Loosli T; Hossmann S; Riedo S; Beerenwinkel N; Jaquet A; Minga A; Ross J; Giandhari J; Kouyos RD; Lessells R BMJ Open; 2024 Aug; 14(8):e085819. PubMed ID: 39174068 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. Castagna A; Ferrara M; Galli L; Comi L; Sterrantino G; Cenderello G; Zaccarelli M; Focà E; Roncadori A; Lazzarin A; J Antimicrob Chemother; 2018 Jan; 73(1):177-182. PubMed ID: 29077927 [TBL] [Abstract][Full Text] [Related]
15. Lamivudine plus dolutegravir as a switch strategy in children: three case reports. Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892 [TBL] [Abstract][Full Text] [Related]
16. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053 [TBL] [Abstract][Full Text] [Related]
18. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV. Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697 [TBL] [Abstract][Full Text] [Related]
19. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204 [TBL] [Abstract][Full Text] [Related]
20. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]